Patients are on a
waiting list in the U.S. alone
Patients die every day
waiting for a lifesaving organ

Already, the Food and Drug Administration has awarded the VP.S ENCORE™ device a Breakthroughh Device Designation, which will allow VPS to bring the technology to market as quickly as possible.

While initially focused on the heart, the VP.S ENCORE™ is a platform device that will extend to other organs and vascularized tissue, allow for Ex-Vivo therapy and provide a basis for future organ banking.

If you are interested in receiving periodic updates, please email us at